Early experience with a prefabricated bioprosthetic aortic valved conduit: The first 100
The prefabricated bioprosthetic aortic valved conduit was used in all settings, including complex reoperations, acute dissection, and endocarditis with acceptable short-term morbidity and mortality. The hemodynamic performance of the valve within the studied period was normal, the long-term durability and hemodynamic performance are yet to be proven.
Authors
- Nishant Saran (ORCID: https://orcid.org/0000-0002-2204-9775)
- Claire Yee (ORCID: https://orcid.org/0000-0003-1601-9163)
- Gabor Bagameri
- Juan A. Crestanello (ORCID: https://orcid.org/0000-0001-5415-1478)
- Malakh Shrestha (ORCID: https://orcid.org/0000-0002-8037-9430)
- Arman Arghami (ORCID: https://orcid.org/0000-0002-7398-0738)
- Philip J. Spencer (ORCID: https://orcid.org/0000-0002-7452-3539)
- Rolando Calderon-Rojas (ORCID: https://orcid.org/0000-0001-7485-6627)
- Joseph A. Dearani (ORCID: https://orcid.org/0000-0002-2664-1290)
- Phillip G. Rowse (ORCID: https://orcid.org/0000-0003-0585-3654)
- Hartzell Vernon Schaff (ORCID: https://orcid.org/0000-0003-0994-027X)
Institutions
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- JTCVS Open
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1016/j.xjon.2025.04.024
- Citations
- 1
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39